Mitsubishi Tanabe Records Additional ¥8.8 Billion For Hepatitis Compensation; President and VP Take Salary Cut
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma announced April 13 a ¥20 billion compensation plan for hepatitis C victims who were infected from tainted blood products manufactured by the company. Last year, Mitsubishi Tanabe set aside ¥11.2 billion for the compensation purpose as a special loss for the third fiscal quarter; the remaining ¥8.8 billion will be recorded as a special write-off for the fourth quarter. To take responsibility for the loss, both the company's president and a vice president will have their salaries reduced by 20 percent for three months, starting in April. (Click here for more - Japanese language
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.